Health & Research Goals
Follistatin 344 (FST-344)
Follistatin
Follistatin 344 is a glycoprotein that functions as a potent antagonist of myostatin, a protein that acts as a negative regulator …
Primary Description
Follistatin 344 is a glycoprotein that functions as a potent antagonist of myostatin, a protein that acts as a negative regulator of muscle growth. By binding to myostatin, Follistatin 344 prevents it from interacting with its receptor, Activin Receptor Type IIB (ActRIIB), on muscle cells. This inhibition of the myostatin signaling pathway leads to an increase in muscle protein synthesis and a decrease in muscle protein breakdown, resulting in muscle hypertrophy and hyperplasia. Beyond its effects on myostatin, Follistatin 344 also inhibits other members of the Transforming Growth Factor-beta (TGF-β) superfamily, such as activin, further contributing to muscle growth and repair. The primary isoform used in research is Follistatin 315 (encoded by the FS344 gene), preferred because it specifically targets muscle tissue with minimal off-target effects due to its poor affinity for heparan sulfate proteoglycans.
Key Benefits
- Muscle growth
- Strength increase
- Fat loss
Lyophilized powder is stable at -20°C for up to 24 months. Reconstituted solution should be stored at 2–8°C and used within 14 days. Avoid repeated freeze-thaw cycles.
Demonstrated Effects
- Potent inhibition of myostatin leading to significant increases in muscle mass and strength
- Stimulates muscle hypertrophy (increased cell size) and hyperplasia (increased cell number)
- Inhibits activin signaling to further support anabolic muscle environment
- Targeted action on muscle tissue with limited off-target systemic effects
- Potential applications in muscle-wasting diseases (sarcopenia, cachexia, DMD)
- Enhanced muscle protein synthesis and reduced muscle protein breakdown
- Reported to produce dramatic muscle gains in animal models (double-muscling phenotype)
- Potential fertility implications via activin pathway modulation
Proposed Mechanisms of Action
1. Myostatin Antagonism (ActRIIB Blockade)
Follistatin binds myostatin with high affinity, preventing its interaction with ActRIIB on muscle cells. Myostatin normally suppresses muscle growth via SMAD2/3 signaling; blocking this pathway releases the brake on muscle protein synthesis.
2. Activin Inhibition
Follistatin also neutralizes activin A and B — TGF-beta superfamily members involved in cell proliferation, differentiation, and apoptosis. Activin inhibition further enhances the muscle anabolic environment.
3. SMAD2/3 Pathway Suppression
By preventing ActRIIB activation, follistatin suppresses SMAD2/3 phosphorylation — the downstream signaling cascade that would otherwise inhibit muscle protein synthesis genes.
4. Satellite Cell Activation
Myostatin suppression (and activin inhibition) disinhibits muscle satellite cells, promoting their proliferation and differentiation into new muscle fibers (hyperplasia).
5. Muscle-Selective Action (FST-315 isoform)
The FST-315 isoform (encoded by FS344 gene) has poor affinity for cell surface heparan sulfate proteoglycans, limiting systemic distribution and targeting effects to muscle tissue.
Research Evidence & Clinical Data
Investigated Applications
Muscle Hypertrophy and Strength
Anecdotal: HighThe primary use case in the biohacker and bodybuilding community. Users report significant muscle size increases, particularly when combined with resistance training. Effects are described as rapid and pronounced compared to other anabolic peptides.
Preclinical basis: Myostatin knockout and follistatin overexpression animal models show dramatic muscle mass increases (200–300% in some studies). Direct ActRIIB blockade prevents myostatin's catabolic muscle signaling.
Muscle-Wasting Disease Research
Anecdotal: EmergingResearch interest exists in applying follistatin as a therapeutic for conditions like Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), sarcopenia, and cancer cachexia where myostatin-mediated muscle loss is pathological.
Preclinical basis: AAV-mediated follistatin gene delivery has produced sustained muscle mass increases in primate models. Human trials ongoing for DMD and inclusion body myositis.
Athletic Recovery and Performance
Anecdotal: ModerateSome community members use follistatin to accelerate recovery from intense training and to break through muscle-building plateaus. The anti-catabolic effect of myostatin suppression is the theoretical basis.
Preclinical basis: Myostatin inhibition reduces muscle damage markers and promotes satellite cell activation during recovery.
Safety Profile
Common Side Effects
- Injection site reactions (redness, swelling)
- Possible disproportionate muscle growth if overused
- Joint strain from rapid muscle mass increase without corresponding connective tissue adaptation
- Limited data
Contraindications
- Pregnancy or breastfeeding — activin pathway critical for reproductive function and fetal development
- Active cancer — growth factor manipulation contraindicated
- Women of childbearing age should use with extreme caution (activin regulates FSH and ovulation)
- Children and adolescents — growth plate effects unknown
- Cardiac conditions
- Cancer
Legal & Regulatory Status
Not approved for human therapeutic use in any jurisdiction. Sold as a research chemical. No scheduled substance status in most countries. WADA prohibited (S0 — Non-Approved Substances). Gene therapy applications (AAV-follistatin) are in FDA-regulated clinical trials for DMD.
No aprobado para uso terapéutico humano en ninguna jurisdicción. Se vende como químico de investigación. Sin estado de sustancia controlada en la mayoría de países. Prohibido por WADA (S0 — Sustancias No Aprobadas). Las aplicaciones de terapia génica (AAV-follistatin) están en ensayos clínicos regulados por la FDA para DMD.
Research Protocols
Dosing Protocols
Routes of Administration
subcutaneous
intramuscular
Reconstitution Guide
Pharmacokinetics
| Half-Life | Approximately 24–36 hours in preclinical models; exact human data not available |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Muscle size and strength tracking weekly
- Joint and connective tissue health — watch for pain from disproportionate muscle-to-tendon growth
- Hormone panel (LH, FSH) if cycle exceeds 2 weeks
- Women: menstrual cycle regularity
- General systemic symptoms (fatigue, mood changes)
Critical Warning Signs
- Disproportionate joint pain from rapid muscle growth — reduce dose or stop
- Menstrual cycle disruption in women — stop and assess hormone panel
- Any new lumps, nodules, or unusual growth — immediate evaluation
- Severe injection site reaction
- Signs of allergic reaction
Featured in Stacking Protocols
Community-researched combinations involving this compound